Antineoplastic Agents, Alkylating
"Antineoplastic Agents, Alkylating" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
MeSH Number(s)
D27.505.519.124.035
D27.505.954.248.150
D27.888.569.035.035
Concept/Terms
Antineoplastic Agents, Alkylating- Antineoplastic Agents, Alkylating
- Antineoplastic Alkylating Agents
- Alkylating Agents, Antineoplastic
- Antineoplastic Drugs, Alkylating
- Antineoplastics, Alkylating
- Alkylating Antineoplastic Drugs
- Alkylating Drugs, Antineoplastic
- Antineoplastic Alkylating Drugs
- Drugs, Antineoplastic Alkylating
- Alkylating Antineoplastic Agents
- Alkylating Antineoplastics
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Alkylating".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Alkylating".
This graph shows the total number of publications written about "Antineoplastic Agents, Alkylating" by people in Harvard Catalyst Profiles by year, and whether "Antineoplastic Agents, Alkylating" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 0 | 3 |
| 1996 | 4 | 3 | 7 |
| 1997 | 3 | 7 | 10 |
| 1998 | 4 | 3 | 7 |
| 1999 | 3 | 6 | 9 |
| 2000 | 4 | 3 | 7 |
| 2001 | 6 | 5 | 11 |
| 2002 | 9 | 2 | 11 |
| 2003 | 11 | 2 | 13 |
| 2004 | 7 | 4 | 11 |
| 2005 | 11 | 6 | 17 |
| 2006 | 9 | 4 | 13 |
| 2007 | 10 | 6 | 16 |
| 2008 | 6 | 5 | 11 |
| 2009 | 7 | 8 | 15 |
| 2010 | 7 | 6 | 13 |
| 2011 | 9 | 13 | 22 |
| 2012 | 8 | 5 | 13 |
| 2013 | 20 | 4 | 24 |
| 2014 | 11 | 7 | 18 |
| 2015 | 12 | 6 | 18 |
| 2016 | 10 | 11 | 21 |
| 2017 | 14 | 6 | 20 |
| 2018 | 7 | 7 | 14 |
| 2019 | 9 | 7 | 16 |
| 2020 | 11 | 5 | 16 |
| 2021 | 4 | 3 | 7 |
| 2022 | 0 | 6 | 6 |
Below are the most recent publications written about "Antineoplastic Agents, Alkylating" by people in Profiles.
-
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro Oncol. 2022 11 02; 24(11):1935-1949.
-
Current therapeutic options for glioblastoma and future perspectives. Expert Opin Pharmacother. 2022 Oct; 23(14):1629-1640.
-
Cognitive function after concurrent temozolomide-based chemoradiation therapy in low-grade gliomas. J Neurooncol. 2022 Jul; 158(3):341-348.
-
Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients. J Neurooncol. 2022 May; 158(1):111-116.
-
PIMREG expression level predicts glioblastoma patient survival and affects temozolomide resistance and DNA damage response. Biochim Biophys Acta Mol Basis Dis. 2022 06 01; 1868(6):166382.
-
Optimizing an effective combination of the new microtubule-targeting agent lisavanbulin with standard-of-care therapy for glioblastoma in patient-derived xenograft preclinical models. Neuro Oncol. 2022 03 12; 24(3):396-397.
-
Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of cytotoxic chemotherapy and other cytotoxic therapies in the management of progressive glioblastoma in adults. J Neurooncol. 2022 Jun; 158(2):225-253.
-
Minimal residual disease in multiple myeloma: why, when, where. Hematology Am Soc Hematol Educ Program. 2021 12 10; 2021(1):37-45.
-
Synthetic control arms in studies of multiple myeloma and diffuse large B-cell lymphoma. Br J Haematol. 2022 03; 196(5):1274-1277.
-
Functional drug susceptibility testing using single-cell mass predicts treatment outcome in patient-derived cancer neurosphere models. Cell Rep. 2021 10 05; 37(1):109788.